Sulfonylurea family members have been used as a second preferred line in the treatment of Type II Diabetes Mellitus (TIIDM) for decades. Only one crystal structure for its receptor Kir6.2\SUR1 binding with one of sulfonylurea member; Glibenclamide (GBM), is available in Protein Data Bank (PDB) database. The aim of this manuscript is to study in-silico other sulfonylurea family members' interactions with their receptor Kir6.2\SUR1 using a docking software in the default settings. We have checked the validity of the software for the study. Then, we have applied a rigid docking on 14 compounds of sulfonyl urea group which they have anti-hyperglycemia activity.
Sulfonylurea compounds' structures were obtained from Pubchem.com database. (Fig 2) Kir 6.2\SUR1 PDB ID used in this research was 6BAA. It was uploaded from Protein Data Bank database. [8] [9] [10] [11] Autodock 4.2.1 software was used for rigid docking process in default settings. PyMol, Chimera, PLIP and LigPlot+ were used for virtual screening and interactions' analyzing.
Validation of the software was done by re-docking in the rigid mode the isolated GBM from its crystal structure with its receptor as follows: 8 Therefore, to do our experiments, we have worked only on one chain of chains (E-H) which is chain F. The binding site residues were obtained from PDB database. 10 It was also studied by PLIP. Each compound of sulfonylurea was docked with the chain F after its sequence of residues was taken down shorthand to include only the binding site of GBM with a number of surrounding residues, 
Results and Discussion:
Glibinclamide (GBM) binding site:
we had the binding site residues from PDB. Fig 7 shows the binding site from PDB in 2d structure using LigPlot+. 
Validation of the method:
After we re-docked the isolated GBM from the crystal structure 6BAA with chain F of the receptor, we have had 8 complexes with 10 conformations ordered according to their binding energy in Table 1 . This can be referred to the fact that Chimera superimposing includes sequences (the number of residues) rather than the residues' geometrical positions. Ordering the compounds according to their scoring function we got Table 3 . In case the compound has many complexes in the binding site, we have chosen the highest scoring function for this compound. Wals bonds as well with almost same residues as GBM.
We have indicated in the previous review that being R1 & R2 small alkyl moieties are probably behind why Tolbutamide is the lowest effective and affinitive to kir6.2\SUR1 compared with other compounds. 13 As Table 2 presents, Tolbutamide is the compound ordered 13 th with its scoring function among sulfonylurea family. Its binding energy is -6.29. Studying its interactions in Table   3 , we find that it does not fit in the whole pocket space, and it has lower interaction with the binding site residues than other compounds have. Tolazamide daily dosage is 10-1000 mg twice a day.
Comparing, Gliclazide, Glibinclamide and Glimipiride, the last compound is considered the most potent among sulfonylurea derivates so far. 14 this can be explained that although its binding energy ( -8.21 ) is less than Glibinclamid's ( -8.5), it is fully absorbed after a dose of 1-4mg a day and it has a long efficacy duration though it is half life is only 4 hours. Its interactions are a higher complexity than the other members. It conforms 8 H-bonds with 3 residues ( ARG 1300, THR 588, TYR 377). It also has strong Van der Wals bonds with LEU 592, PHE433 and TRP 430, whereas weak ones with ILEU 381,ALA 380,HIS 584, VAL 1587, MET 1290, PHE 591, TRP 1297.
